Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Inja Waldhauer, Valeria Gonzalez‐Nicolini, Anne Freimoser–Grundschober, et al.
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Targeting the tumor stroma for cancer therapy
Maosen Xu, Tao Zhang, Ruolan Xia, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 156
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Laura Codarri, Valeria Nicolini, Masao Hashimoto, et al.
Nature (2022) Vol. 610, Iss. 7930, pp. 161-172
Open Access | Times Cited: 153
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials
Hao Zhang, Xinghai Yue, Zhe Chen, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 142
Advances in antibody-based therapy in oncology
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Cancer (2023) Vol. 4, Iss. 2, pp. 165-180
Closed Access | Times Cited: 119
Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures
Bing Feng, Jian Wu, Bo Shen, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 112
Emerging principles of cytokine pharmacology and therapeutics
Robert A. Saxton, Caleb R. Glassman, K. Christopher García
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 21-37
Open Access | Times Cited: 110
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Lana E. Kandalaft, Denarda Dangaj, George Coukos
Nature reviews. Cancer (2022) Vol. 22, Iss. 11, pp. 640-656
Closed Access | Times Cited: 100
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
Miro E. Raeber, Dilara Şahin, Ufuk Karakus, et al.
EBioMedicine (2023) Vol. 90, pp. 104539-104539
Open Access | Times Cited: 94
Strategies to therapeutically modulate cytokine action
Warren J. Leonard, Jian‐Xin Lin
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 10, pp. 827-854
Closed Access | Times Cited: 56
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 35
Evolution of cell therapy for renal cell carcinoma
Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 25
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
The tumor microenvironment: a key player in multidrug resistance in cancer
Lingnan Meng, Ying Zheng, Hao Liu, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 1, pp. 41-58
Open Access | Times Cited: 15
Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?
Masaya Yamazaki, Takatsugu Ishimoto
Cancer Science (2025)
Open Access | Times Cited: 3
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
Alfredo Quijano‐Rubio, M. Aladdin Bhuiyan, Huilin Yang, et al.
Nature Biotechnology (2022) Vol. 41, Iss. 4, pp. 532-540
Open Access | Times Cited: 51
Interleukin-2–based therapies in cancer
Miro E. Raeber, Dilara Şahin, Onur Boyman
Science Translational Medicine (2022) Vol. 14, Iss. 670
Closed Access | Times Cited: 49
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
Elisa Rivas, Jenniffer Linares, Melissa Zwick, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 46
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Jiaojiao Ni, Zizhen Zhang, Ming-jie Ge, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 2, pp. 288-307
Open Access | Times Cited: 39
Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
Ying Zhou, Yuxin Guo, Lufei Chen, et al.
Theranostics (2022) Vol. 12, Iss. 12, pp. 5488-5503
Open Access | Times Cited: 38
Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy
Sedigheh Shahvali, Niloufar Rahiman, Mahmoud Reza Jaafari, et al.
Drug Delivery and Translational Research (2023) Vol. 13, Iss. 7, pp. 2041-2056
Closed Access | Times Cited: 36
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 13
Open Access | Times Cited: 31
Heterogeneity of cancer-associated fibroblasts in head and neck squamous cell carcinoma: opportunities and challenges
Hu Chen, Yifan Zhang, Chunping Wu, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 27
The application of Interleukin-2 family cytokines in tumor immunotherapy research
Yangyihua Zhou, Guiqi Quan, Yujun Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Kelly D. Moynihan, Manu P. Kumar, Hussein Sultan, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1206-1225
Open Access | Times Cited: 13
Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies
Sebastian Dziadek, Anton Kraxner, Wei‐Yi Cheng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top